##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549



---



Form 10-Q



---



QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934



For the quarter ended June 30, 2005



Commission file number 1-14643



---



LOGO



STERIS Corporation

(Exact name of registrant as specified in its charter)



---



|                                                               |  |                                  
|-------------------------------------------------------------- |  | ---------------------------------
|Ohio                                                           |  | 34-1482024                       
|(State or other jurisdiction of incorporation or organization) |  | (IRS Employer Identification No.)



|                                         |  |           
|---------------------------------------- |  | ----------
|5960 Heisley Road, Mentor, Ohio          |  | 44060-1834
|(Address of principal executive offices) |  | (Zip code)



440-354-2600

(Registrants telephone number, Including area code)



---



Indicate by
check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No ̈



Indicate
by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    Yes  x    No ̈



The number of Common Shares outstanding as of July 31, 2005: 68,126,781



---



---

##### Table of Contents

STERIS Corporation

Form 10-Q

Index



|                               |  |                                                                                       |  |   
|------------------------------ |  | ------------------------------------------------------------------------------------- |  | --
|                               |  | Page                                                                                 
|Part I - Financial Information |  |                                                                                      
|                               |  |                                                                                      
|Item 1.                        |  | Financial Statements                                                                  |  | 3 
|                               |  |                                                                                      
|Item 2.                        |  | Managements Discussion and Analysis of Financial Condition and Results of Operations |  | 17
|                               |  |                                                                                      
|Item 3.                        |  | Quantitative and Qualitative Disclosures About Market Risk                            |  | 27
|                               |  |                                                                                      
|Item 4.                        |  | Controls and Procedures                                                               |  | 27
|                               | 
|Part II - Other Information    |  |                                                                                      
|                               |  |                                                                                      
|Item 1.                        |  | Legal Proceedings                                                                     |  | 28
|                               |  |                                                                                      
|Item 2.                        |  | Unregistered Sales of Equity Securities and Use of Proceeds                           |  | 28
|                               |  |                                                                                      
|Item 6.                        |  | Exhibits                                                                              |  | 29
|                               |  |                                                                                      
|                               |  | Signature                                                                             |  | 31



---

##### Table of Contents

PART I - FINANCIAL INFORMATION



ITEM 1. FINANCIAL STATEMENTS



STERIS CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands)



|                                                                                                                              |  |               |           |   |               |   |           |  
|----------------------------------------------------------------------------------------------------------------------------- |  | ------------- | --------- | - | ------------- | - | --------- | -
|                                                                                                                              |  | June 30, 2005 |           |   | March 31,2005 |  
|                                                                                                                              |  | (Unaudited)   |           |   |               |  
|Assets                                                                                                                        |  |               |           |   |               |   |           |  
|                                                                                                                              |  |              
|Current assets:                                                                                                               |  |               |           |   |               |   |           |  
|Cash and cash equivalents                                                                                                     |  | $             | 37,453    |   |               | $ | 26,179    |  
|Accounts receivable (net of allowances of $8,671 and $9,882, respectively)                                                    |  |               | 225,605   |   |               |   | 281,401   |  
|Inventories, net                                                                                                              |  |               | 110,074   |   |               |   | 96,197    |  
|Current portion of deferred income taxes, net                                                                                 |  |               | 6,800     |   |               |   | 6,426     |  
|Prepaid expenses and other current assets                                                                                     |  |               | 12,956    |   |               |   | 9,929     |  
|                                                                                                                              |  |               |           |   |               |   |           |  
|Total current assets                                                                                                          |  |               | 392,888   |   |               |   | 420,132   |  
|                                                                                                                              |  |              
|Property, plant, and equipment, net                                                                                           |  |               | 406,431   |   |               |   | 413,578   |  
|Goodwill and intangibles, net                                                                                                 |  |               | 341,006   |   |               |   | 350,156   |  
|Other assets                                                                                                                  |  |               | 1,868     |   |               |   | 1,856     |  
|                                                                                                                              |  |               |           |   |               |   |           |  
|Total assets                                                                                                                  |  | $             | 1,142,193 |   |               | $ | 1,185,722 |  
|                                                                                                                              |  |               |           |   |               |   |           |  
|Liabilities and shareholders equity                                                                                          |  |               |           |   |               |   |           |  
|                                                                                                                              |  |              
|Current liabilities:                                                                                                          |  |               |           |   |               |   |           |  
|Current portion of long-term indebtedness                                                                                     |  | $             | 3,166     |   |               | $ | 4,889     |  
|Accounts payable                                                                                                              |  |               | 56,306    |   |               |   | 67,550    |  
|Accrued income taxes                                                                                                          |  |               | 17,907    |   |               |   | 13,474    |  
|Accrued payroll and other related liabilities                                                                                 |  |               | 32,515    |   |               |   | 41,716    |  
|Accrued expenses and other                                                                                                    |  |               | 79,611    |   |               |   | 94,186    |  
|                                                                                                                              |  |               |           |   |               |   |           |  
|Total current liabilities                                                                                                     |  |               | 189,505   |   |               |   | 221,815   |  
|                                                                                                                              |  |              
|Long-term indebtedness                                                                                                        |  |               | 125,717   |   |               |   | 104,274   |  
|Deferred income taxes, net                                                                                                    |  |               | 38,690    |   |               |   | 38,862    |  
|Other liabilities                                                                                                             |  |               | 65,411    |   |               |   | 65,133    |  
|                                                                                                                              |  |               |           |   |               |   |           |  
|Total liabilities                                                                                                             |  |               | 419,323   |   |               |   | 430,084   |  
|                                                                                                                              |  |              
|Serial preferred shares, without par value; 3,000 shares authorized; no shares issued or outstanding                          |  |               |          |   |               |   |          |  
|Common shares, without par value; 300,000 shares authorized; issued and outstanding shares of 68,096 and 69,627, respectively |  |               | 174,177   |   |               |   | 211,657   |  
|Retained earnings                                                                                                             |  |               | 552,091   |   |               |   | 537,526   |  
|Accumulated other comprehensive income (loss):                                                                                |  |               |           |   |               |   |           |  
|Minimum pension liability                                                                                                     |  |               | (5,974    | ) |               |   | (5,974    | )
|Cumulative foreign currency translation adjustments                                                                           |  |               | 2,576     |   |               |   | 12,429    |  
|                                                                                                                              |  |               |           |   |               |   |           |  
|Total shareholders equity                                                                                                    |  |               | 722,870   |   |               |   | 755,638   |  
|                                                                                                                              |  |               |           |   |               |   |           |  
|Total liabilities and shareholders equity                                                                                    |  | $             | 1,142,193 |   |               | $ | 1,185,722 |  
|                                                                                                                              |  |               |           |   |               |   |           |  



See notes to
consolidated financial statements.



3



---

##### Table of Contents

STERIS CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share amounts)

(Unaudited)



|                                                     |  |                            |         |   |      |   |        
|---------------------------------------------------- |  | -------------------------- | ------- | - | ---- | - | -------
|                                                     |  | Three Months EndedJune 30,
|                                                     |  | 2005                       |         |   | 2004
|Revenues:                                            |  |                            |         |   |      |   |        
|Product                                              |  | $                          | 176,920 |   |      | $ | 168,425
|Service                                              |  |                            | 99,778  |   |      |   | 86,372 
|                                                     |  |                            |         |   |      |   |        
|Total revenues                                       |  |                            | 276,698 |   |      |   | 254,797
|                                                     |  |                           
|Cost of revenues:                                    |  |                            |         |   |      |   |        
|Product                                              |  |                            | 101,638 |   |      |   | 95,194 
|Service                                              |  |                            | 57,289  |   |      |   | 49,711 
|                                                     |  |                            |         |   |      |   |        
|Total cost of revenues                               |  |                            | 158,927 |   |      |   | 144,905
|                                                     |  |                            |         |   |      |   |        
|Gross profit                                         |  |                            | 117,771 |   |      |   | 109,892
|                                                     |  |                           
|Operating expenses:                                  |  |                            |         |   |      |   |        
|Selling, general, and administrative                 |  |                            | 81,793  |   |      |   | 72,566 
|Research and development                             |  |                            | 8,729   |   |      |   | 9,311  
|                                                     |  |                            |         |   |      |   |        
|Total operating expenses                             |  |                            | 90,522  |   |      |   | 81,877 
|                                                     |  |                            |         |   |      |   |        
|Income from operations                               |  |                            | 27,249  |   |      |   | 28,015 
|Non-operating (income) expense, net                  |  |                            | (706    | ) |      |   | 701    
|                                                     |  |                            |         |   |      |   |        
|Income before income tax expense                     |  |                            | 27,955  |   |      |   | 27,314 
|                                                     |  |                           
|Income tax expense                                   |  |                            | 10,623  |   |      |   | 9,697  
|                                                     |  |                            |         |   |      |   |        
|Net income                                           |  | $                          | 17,332  |   |      | $ | 17,617 
|                                                     |  |                            |         |   |      |   |        
|Net income per common share:                         |  |                            |         |   |      |   |        
|Basic                                                |  | $                          | 0.25    |   |      | $ | 0.25   
|                                                     |  |                            |         |   |      |   |        
|Diluted                                              |  | $                          | 0.25    |   |      | $ | 0.25   
|                                                     |  |                            |         |   |      |   |        
|Cash dividends declared per common share outstanding |  | $                          | 0.04    |   |      | $ |       
|                                                     |  |                            |         |   |      |   |        



See notes to
consolidated financial statements.



4



---

##### Table of Contents

STERIS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)



|                                                                                             |  |                            |         |   |      |   |         |  
|-------------------------------------------------------------------------------------------- |  | -------------------------- | ------- | - | ---- | - | ------- | -
|                                                                                             |  | Three Months EndedJune 30, |        
|                                                                                             |  | 2005                       |         |   | 2004 |  
|Operating activities:                                                                        |  |                            |         |   |      |   |         |  
|Net income                                                                                   |  | $                          | 17,332  |   |      | $ | 17,617  |  
|Adjustments to reconcile net income to net cash provided by operating activities:            |  |                            |         |   |      |   |         |  
|Depreciation, depletion, and amortization                                                    |  |                            | 13,893  |   |      |   | 11,702  |  
|Deferred income taxes                                                                        |  |                            | (215    | ) |      |   | 4,379   |  
|Other items                                                                                  |  |                            | (549    | ) |      |   | 1,817   |  
|Changes in operating assets and liabilities, excluding the effects of business acquisitions: |  |                            |         |   |      |   |         |  
|Accounts receivable, net                                                                     |  |                            | 55,544  |   |      |   | 17,970  |  
|Inventories, net                                                                             |  |                            | (12,407 | ) |      |   | (3,623  | )
|Other current assets                                                                         |  |                            | (2,557  | ) |      |   | (3,889  | )
|Accounts payable                                                                             |  |                            | (14,179 | ) |      |   | (7,184  | )
|Accruals and other, net                                                                      |  |                            | (15,769 | ) |      |   | 3,453   |  
|                                                                                             |  |                            |         |   |      |   |         |  
|Net cash provided by operating activities                                                    |  |                            | 41,093  |   |      |   | 42,242  |  
|                                                                                             |  |                           
|Investing activities:                                                                        |  |                            |         |   |      |   |         |  
|Purchases of property, plant, equipment, and intangibles, net                                |  |                            | (8,144  | ) |      |   | (10,545 | )
|                                                                                             |  |                            |         |   |      |   |         |  
|Net cash used in investing activities                                                        |  |                            | (8,144  | ) |      |   | (10,545 | )
|                                                                                             |  |                           
|Financing activities:                                                                        |  |                            |         |   |      |   |         |  
|Proceeds (payments) under credit facilities, net                                             |  |                            | 21,600  |   |      |   | (5,247  | )
|Payments on long-term obligations and capital leases, net                                    |  |                            | (1,675  | ) |      |   | (1,118  | )
|Repurchases of common shares                                                                 |  |                            | (39,394 | ) |      |   | (28,149 | )
|Cash dividends paid to common shareholders                                                   |  |                            | (2,767  | ) |      |   |        |  
|Deferred financing fees                                                                      |  |                            | (217    | ) |      |   |        |  
|Stock option and other equity transactions, net                                              |  |                            | 1,603   |   |      |   | 2,646   |  
|                                                                                             |  |                            |         |   |      |   |         |  
|Net cash used in financing activities                                                        |  |                            | (20,850 | ) |      |   | (31,868 | )
|                                                                                             |  |                           
|Effect of exchange rate changes on cash and cash equivalents                                 |  |                            | (825    | ) |      |   | (311    | )
|                                                                                             |  |                            |         |   |      |   |         |  
|Increase (decrease) in cash and cash equivalents                                             |  |                            | 11,274  |   |      |   | (482    | )
|Cash and cash equivalents at beginning of period                                             |  |                            | 26,179  |   |      |   | 80,408  |  
|                                                                                             |  |                            |         |   |      |   |         |  
|Cash and cash equivalents at end of period                                                   |  | $                          | 37,453  |   |      | $ | 79,926  |  
|                                                                                             |  |                            |         |   |      |   |         |  



See notes to
consolidated financial statements.



5



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



1. Nature of Operations and Summary of Significant Accounting
Policies



Throughout this document, references to
STERIS Corporation, STERIS, or the Company, are references to STERIS Corporation and its subsidiaries, except where a different meaning is clearly required by the context. The Companys fiscal year ends on
March 31. References to a particular year or year-end refer to the Companys fiscal year.



Nature of Operations



The Company develops, manufactures, and markets a combination of equipment, consumables, and services for healthcare, pharmaceutical, scientific,
research, industrial, and governmental customers throughout the world. The Company operates in three business segments: Healthcare, Life Sciences, and STERIS Isomedix Services.



Interim Financial Statements



The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting
principles for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for
complete financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) necessary to present fairly the
financial condition, results of operations, and cash flows of the Company for the periods presented.



These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the
Companys Annual Report on Form 10-K for the year ended March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005. The Consolidated Balance Sheet at March 31, 2005 has been derived from the audited consolidated
financial statements at that date, but does not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements.



Principles of Consolidation



The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Significant inter-company accounts and
transactions have been eliminated upon consolidation.



Use of Estimates



The preparation of financial statements in conformity
with U.S. generally accepted accounting principles requires management to make estimates and assumptions in certain circumstances that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates and, therefore, operating results for the three-month period ended June 30, 2005 are not necessarily indicative of results that may be
expected for the full fiscal year ending March 31, 2006.



Reclassifications



Certain prior period
amounts have been reclassified to conform to the current periods presentation. Further information regarding reclassifications of segment revenues and segment operating results is included in Note 11, Business Segment Information.



Significant Accounting Policies



A detailed description of the Companys significant and critical
accounting policies, estimates, and assumptions is included in the Companys Annual Report on Form 10-K for the year ended March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005. The Companys significant and
critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2005.



6



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



Share-Based Compensation



The Company has granted nonqualified stock options to certain employees to
purchase the Companys common shares at the market price on the date of grant. Stock options granted generally become exercisable to the extent of one-fourth of the optioned shares for each full year of employment following the date of grant
and generally expire 10 years after the date of grant, or earlier if an option holder ceases to be employed by the Company. Certain option agreements have provisions that provide for an adjustment to the normal vesting schedule whereby options vest
on a prorated basis as defined by specific option agreements in the event of employment termination. The Company accounts for share-based compensation under the provisions of Accounting Principles Board Opinion No. 25 (APB No. 25),
Accounting for Stock Issued to Employees, as permitted by Statement of Financial Accounting Standards No. 123 (SFAS No. 123), Accounting for Stock-Based Compensation, as amended by Statement of Financial
Accounting Standards No. 148, Accounting for Stock-Based Compensation - Transition and Disclosure, and accordingly recognizes no compensation expense when the exercise price equals the market price of the stock on the date of grant.



In December 2004, the Financial Accounting Standards Board
issued Statement of Financial Accounting Standards No. 123R (SFAS No. 123R), Share-Based Payment, which is a revision of SFAS No. 123. This revised standard supersedes APB No. 25 and amends Statement of Financial Accounting
Standards No. 95, Statement of Cash Flows. This revised standard addresses the accounting for share-based payment transactions in which a company receives employee services in exchange for either equity instruments of the company or
liabilities that are based on the fair value of the companys equity instruments. Under the revised standard, companies will no longer be able to account for such transactions using the intrinsic value method in accordance with APB No. 25.
Instead, companies will be required to account for such transactions using a fair value method and recognize expense in the consolidated statements of income. In addition, the revised standard requires that the benefits of tax deductions in excess
of recognized compensation cost be reported as a financing cash flow, rather than as an operating cash flow as required under current accounting guidance. This requirement will reduce net operating cash flows and will increase net financing cash
flows in periods after adoption. The Company cannot estimate what these amounts will be in the future because they depend on, among other things, when employees exercise stock options. However, the amount of operating cash flows recognized in prior
periods for these excess tax deductions has historically not been material. SFAS No. 123R is effective for annual reporting periods beginning after June 15, 2005. The Company will adopt SFAS No. 123R on April 1, 2006. The Company has not yet
determined which fair value model and transitional provision it will follow.



The following table contains pro forma disclosures regarding the effect on the Companys net income, earnings per basic common share, and earnings per diluted common share had the Company applied a fair value
method of accounting for share-based compensation in accordance with SFAS No. 123. Depending on the model used to calculate share-based compensation expense in the future and other requirements of SFAS No. 123R, the pro forma disclosures currently
used by the Company may not be indicative of the share-based compensation expense that will be recognized in the Companys future financial statements. Further, the structure and timing of future grants may also have differing impacts on future
results.



7



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



|                                                                                            |  |                            |        |      |   |       
|------------------------------------------------------------------------------------------- |  | -------------------------- | ------ | ---- | - | ------
|                                                                                            |  | Three Months EndedJune 30,
|                                                                                            |  | 2005                       |        | 2004
|Net income:                                                                                 |  |                            |        |      |   |       
|As reported                                                                                 |  | $                          | 17,332 |      | $ | 17,617
|Less: Stock-based compensation expense, net of income taxes, assuming the fair value method |  |                            | 1,476  |      |   | 1,457 
|                                                                                            |  |                            |        |      |   |       
|Pro forma                                                                                   |  | $                          | 15,856 |      | $ | 16,160
|                                                                                            |  |                            |        |      |   |       
|Earnings per common share:                                                                  |  |                            |        |      |   |       
|Basic:                                                                                      |  |                            |        |      |   |       
|As reported                                                                                 |  | $                          | 0.25   |      | $ | 0.25  
|Pro forma                                                                                   |  |                            | 0.23   |      |   | 0.23  
|Diluted:                                                                                    |  |                            |        |      |   |       
|As reported                                                                                 |  |                            | 0.25   |      |   | 0.25  
|Pro forma                                                                                   |  |                            | 0.23   |      |   | 0.23  



For the purpose of
computing pro forma net income, the fair value of option grants was estimated at their grant date using the Black-Scholes option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting
restrictions and are fully transferable, characteristics that are not present in the Companys option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value
of the stock options could be different.



2. Common Shares



Basic earnings per common share is calculated based upon the
weighted average number of common shares outstanding. Diluted earnings per common share is calculated based upon the weighted average number of common shares outstanding plus the dilutive effect of common share equivalents calculated using the
treasury stock method. The following is a summary of common shares and common share equivalents outstanding used in the calculations of basic and diluted earnings per common share:



|                                                                                  |  |                            |  |       
|--------------------------------------------------------------------------------- |  | -------------------------- |  | ------
|                                                                                  |  | Three Months EndedJune 30,
|                                                                                  |  | 2005                       |  | 2004  
|                                                                                  |  | (shares in thousands)     
|Weighted average common shares outstanding - basic                                |  | 69,127                     |  | 69,475
|Dilutive effect of common share equivalents                                       |  | 759                        |  | 967   
|                                                                                  |  |                            |  |       
|Weighted average common shares outstanding and common share equivalents - diluted |  | 69,886                     |  | 70,442
|                                                                                  |  |                            |  |       



Options to purchase
the following number of common shares at the following weighted average exercise prices were outstanding but excluded from the computation of diluted earnings per common share because the exercise prices were greater than the average market price
for the common shares during the period:



|                                |  |                            |       |      |   |      
|------------------------------- |  | -------------------------- | ----- | ---- | - | -----
|                                |  | Three Months EndedJune 30,
|                                |  | 2005                       |       | 2004
|                                |  | (shares in thousands)     
|Number of common share options  |  |                            | 1,396 |      |   | 1,488
|Weighted average exercise price |  | $                          | 28.56 |      | $ | 28.67



8



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



3. Comprehensive Income



Statement of Financial Accounting Standards No. 130, Reporting
Comprehensive Income, establishes standards for reporting comprehensive income. Comprehensive income includes net income as currently reported under U.S. generally accepted accounting principles and other comprehensive income. Other
comprehensive income considers the effects of additional economic events that are not required to be recorded in determining net income, but rather are reported as a separate component of shareholders equity. The following table illustrates
the components of the Companys comprehensive income:



|                                         |  |                            |        |   |      |   |        |  
|---------------------------------------- |  | -------------------------- | ------ | - | ---- | - | ------ | -
|                                         |  | Three Months EndedJune 30, |       
|                                         |  | 2005                       |        |   | 2004 |  
|Net income                               |  | $                          | 17,332 |   |      | $ | 17,617 |  
|Foreign currency translation adjustments |  |                            | (9,853 | ) |      |   | (1,460 | )
|                                         |  |                            |        |   |      |   |        |  
|Total comprehensive income               |  | $                          | 7,479  |   |      | $ | 16,157 |  
|                                         |  |                            |        |   |      |   |        |  



4. Depreciable Assets



Information related to the major categories of the
Companys depreciable assets is as follows:



|                                             |  |              |          |   |               |   |          |  
|-------------------------------------------- |  | ------------ | -------- | - | ------------- | - | -------- | -
|                                             |  | June 30,2005 |          |   | March 31,2005 |  
|Land and land improvements (1)               |  | $            | 23,893   |   |               | $ | 23,518   |  
|Buildings and leasehold improvements         |  |              | 193,093  |   |               |   | 195,727  |  
|Machinery and equipment                      |  |              | 250,680  |   |               |   | 242,009  |  
|Information systems                          |  |              | 97,819   |   |               |   | 97,665   |  
|Radioisotope                                 |  |              | 111,629  |   |               |   | 108,519  |  
|Construction in progress (1)                 |  |              | 37,071   |   |               |   | 36,973   |  
|                                             |  |              |          |   |               |   |          |  
|Total property, plant, and equipment         |  |              | 714,185  |   |               |   | 704,411  |  
|Less: accumulated depreciation and depletion |  |              | (307,754 | ) |               |   | (290,833 | )
|                                             |  |              |          |   |               |   |          |  
|Property, plant, and equipment, net          |  | $            | 406,431  |   |               | $ | 413,578  |  
|                                             |  |              |          |   |               |   |          |  

---

|(1) | Land is not depreciated. Construction in progress is not depreciated until placed in service.
|--- | ---------------------------------------------------------------------------------------------



5. Inventories, Net



Inventories are stated at the lower of cost or market. The Company uses the last-in, first-out (LIFO) and first-in, first-out (FIFO) cost methods. An
actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on managements estimates of expected year-end
inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:



|                 |  |              |         |               |   |       
|---------------- |  | ------------ | ------- | ------------- | - | ------
|                 |  | June 30,2005 |         | March 31,2005
|Raw materials    |  | $            | 30,528  |               | $ | 26,769
|Work in process  |  |              | 27,256  |               |   | 23,533
|Finished goods   |  |              | 52,290  |               |   | 45,895
|                 |  |              |         |               |   |       
|Inventories, net |  | $            | 110,074 |               | $ | 96,197
|                 |  |              |         |               |   |       



9



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



6. Debt



Indebtedness was as follows:



|                      |  |              |         |               |   |        
|--------------------- |  | ------------ | ------- | ------------- | - | -------
|                      |  | June 30,2005 |         | March 31,2005
|Private Placement     |  | $            | 100,000 |               | $ | 100,000
|Credit facility       |  |              | 22,800  |               |   | 1,200  
|Other debt            |  |              | 6,083   |               |   | 7,963  
|                      |  |              |         |               |   |        
|Total                 |  |              | 128,883 |               |   | 109,163
|Less: current portion |  |              | 3,166   |               |   | 4,889  
|                      |  |              |         |               |   |        
|Long-term portion     |  | $            | 125,717 |               | $ | 104,274
|                      |  |              |         |               |   |        



As of June 16, 2005,
the Company entered into Amendment No. 2 (Amendment No. 2) to the Amended and Restated Credit Agreement (the Credit Agreement) dated March 29, 2004 with KeyBank National Association, as administrative agent for the lending
institutions party thereto, and with such lending institutions. Among other things, Amendment No. 2 modified the Companys existing Credit Agreement to amend the facility fee rates and applicable margins, extend the length of the facility to
June 15, 2010, increase the swing line commitment component of the Credit Facility to $35.0 million, and relax certain covenants.



Additional information regarding the Companys indebtedness is included in the Companys Annual Report on Form 10-K for the year ended March 31,
2005, filed with the Securities and Exchange Commission on June 14, 2005.



7. Additional Consolidated Balance Sheets Information



Additional information related to the Companys Consolidated Balance Sheets is as follows:



|                                                    |  |              |        |               |   |       
|--------------------------------------------------- |  | ------------ | ------ | ------------- | - | ------
|                                                    |  | June 30,2005 |        | March 31,2005
|Accrued payroll and other related liabilities:      |  |              |        |               |   |       
|Compensation and related items                      |  | $            | 12,351 |               | $ | 12,435
|Accrued vacation                                    |  |              | 12,741 |               |   | 12,967
|Accrued bonuses                                     |  |              | 2,428  |               |   | 7,697 
|Accrued employee commissions                        |  |              | 4,995  |               |   | 8,617 
|                                                    |  |              |        |               |   |       
|Total accrued payroll and other related liabilities |  | $            | 32,515 |               | $ | 41,716
|                                                    |  |              |        |               |   |       
|Accrued expenses and other:                         |  |              |        |               |   |       
|Deferred revenues                                   |  | $            | 22,511 |               | $ | 34,376
|Self-insured risk retention-GRIC                    |  |              | 15,885 |               |   | 16,315
|Other self-insured risks                            |  |              | 872    |               |   | 1,265 
|Retirement benefit obligations-current portion      |  |              | 9,338  |               |   | 9,342 
|Accrued dealer commissions                          |  |              | 4,393  |               |   | 4,589 
|Accrued warranty                                    |  |              | 6,460  |               |   | 6,230 
|Other                                               |  |              | 20,152 |               |   | 22,069
|                                                    |  |              |        |               |   |       
|Total accrued expenses and other                    |  | $            | 79,611 |               | $ | 94,186
|                                                    |  |              |        |               |   |       
|Other liabilities:                                  |  |              |        |               |   |       
|Retirement benefit obligations-long-term portion    |  | $            | 65,411 |               | $ | 65,133
|                                                    |  |              |        |               |   |       
|Total other liabilities                             |  | $            | 65,411 |               | $ | 65,133
|                                                    |  |              |        |               |   |       



10



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



8. Income Tax Expense



Income tax expense includes U.S. federal, state and local, and
foreign income taxes, and is based on reported pre-tax income. Income tax expense is provided on an interim basis based upon the Companys estimate of the annual effective income tax rate. In determining the estimated annual effective income
tax rate, the Company analyzes various factors, including projections of the Companys annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the Companys ability to
use tax credits and net operating loss carryforwards, and available tax planning alternatives. The effective income tax rates for the three months ended June 30, 2005 and 2004 were 38.0% and 35.5%, respectively. The higher effective income tax rate
for the three-month period ended June 30, 2005 is a result of a reduction in operating profits generated in international tax jurisdictions and the resulting inability of the Company to utilize a portion of foreign tax credits against foreign
profits taxed in the United States.



9. Benefit Plans



The Company provides defined benefit pension plans
for certain manufacturing and plant administrative personnel throughout the world as determined by collective bargaining agreements or employee benefit standards set at the time of acquisition of certain businesses. In addition to providing pension
benefits to certain employees, the Company sponsors an unfunded post-retirement medical benefit plan for two groups of U.S. employees comprised substantially of the same employees who receive pension benefits under the U.S. defined benefit pension
plans. Benefits under this plan include retiree life insurance and retiree medical insurance, including prescription drug coverage and Medicare supplemental coverage. Additional information regarding the Companys defined benefit pension plans
and other post-retirement medical benefit plan is included in the Companys Annual Report on Form 10-K for the year ended March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005.



Components of the net periodic benefit cost of the Companys defined
benefit pension plans and other post-retirement medical benefit plan were as follows:



|                               |  |                               |      |   |                            |   |      |      |  |   |      |   |  |      |     |      |  |   |       |  |   |      
|------------------------------ |  | ----------------------------- | ---- | - | -------------------------- | - | ---- | ---- |  | - | ---- | - |  | ---- | --- | ---- |  | - | ----- |  | - | -----
|                               |  | Defined Benefit Pension Plans |      |   | Other Post-Retirement Plan
|                               |  | U.S. Qualified                |      |   | International              |   |     
|Three Months Ended June 30,    |  | 2005                          |      |   | 2004                       |   |      | 2005 |  |   | 2004 |   |  | 2005 |     | 2004
|Service cost                   |  | $                             | 222  |   |                            | $ | 213  |      |  | $ | 184  |   |  | $    | 164 |      |  | $ | 272   |  | $ | 235  
|Interest cost                  |  |                               | 646  |   |                            |   | 649  |      |  |   | 143  |   |  |      | 144 |      |  |   | 1,134 |  |   | 1,172
|Expected return on plan assets |  |                               | (697 | ) |                            |   | (733 | )    |  |   | (85  | ) |  |      | (89 | )    |  |   |      |  |   |     
|Net amortization and deferral  |  |                               | 209  |   |                            |   | 144  |      |  |   |     |   |  |      |    |      |  |   | 438   |  |   | 476  
|                               |  |                               |      |   |                            |   |      |      |  |   |      |   |  |      |     |      |  |   |       |  |   |      
|Net periodic benefit cost      |  | $                             | 380  |   |                            | $ | 273  |      |  | $ | 242  |   |  | $    | 219 |      |  | $ | 1,844 |  | $ | 1,883
|                               |  |                               |      |   |                            |   |      |      |  |   |      |   |  |      |     |      |  |   |       |  |   |      



It is the
Companys practice to fund amounts for the defined benefit pension plans at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws. Liabilities for amounts in excess of these funding
levels are included on the accompanying Consolidated Balance Sheets of the Company. As of June 30, 2005, the Company does not expect to make contributions to the defined benefit pension plans during fiscal 2006.



In December 2003, the Medicare Prescription Drug, Improvement and
Modernization Act of 2003 (the Act) was signed into law. The Act expands Medicare benefits, primarily adding a prescription drug benefit for Medicare-eligible retirees beginning in 2006, as well as a federal subsidy to sponsors of
retiree healthcare benefit plans that provide a benefit that is at least actuarially equivalent to Medicare Part D. In May 2004, the Financial Accounting Standards Board issued FASB Staff Position No. 106-2 (FSP No. 106-2),
Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, which provides guidance on the accounting for the effects of the Act. The Company adopted FSP No. 106-2 on March
31, 2005. The effects of the adoption resulted in a reduction of $10,500 to the Companys accumulated other post-retirement benefit obligation at March 31, 2005. This amount is being amortized over approximately twelve years. For the quarter
ended June 30, 2005, the effects of the adoption of FSP No. 106-2 resulted in a reduction of the Companys net periodic benefit cost of $225.



11



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



10. Contingencies



The Company is involved in various patent, product liability, consumer,
environmental, tax proceedings and claims, governmental investigations, and other legal and regulatory proceedings that arise from time to time in the ordinary course of business. In accordance with Statement of Financial Accounting Standards No. 5,
Accounting for Contingencies, the Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is both probable and estimable. The Company considers many factors in making these
assessments, including the professional judgment of experienced members of management and the Companys legal counsel. The Company has made estimates as to the likelihood of unfavorable outcomes and the amounts of such potential losses. In the
opinion of management, the ultimate outcome of these proceedings and claims is not anticipated to have a material adverse effect on the Companys consolidated financial position, results of operations, or cash flows. Litigation is inherently
unpredictable and actual results could materially differ from the Companys estimates. The Company records anticipated recoveries under applicable insurance contracts when assured of recovery.



To the extent that management of the Company believes it is probable that a
taxing authority will take a sustainable position on a matter contrary to the position taken by the Company, the Company provides tax accruals. If the Company was to prevail in matters for which accruals have been established, or is required to pay
amounts in excess of established accruals, the Companys effective income tax rate in a given financial statement period could be materially impacted.



Refer to Part II, Item 1, Legal Proceedings, on page 28 of this Form 10-Q.



11. Business Segment Information



The Company operates and reports in three business segments: Healthcare,
Life Sciences, and STERIS Isomedix Services. Operating income (loss) for each of the Companys reportable business segments reflects the full allocation of all distribution, corporate, and research and development expenses to the reportable
segments. These allocations are based upon variables such as segment headcount and revenues. The accounting policies for reportable segments are the same as those for the consolidated Company. For the quarter ended June 30, 2005, revenues from a
single customer did not represent ten percent or more of the respective segments revenues. Additional information regarding the Companys business segments is included in the Companys Annual Report on Form 10-K for the year ended
March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005.



Segment Service Reclassification



Effective April 1, 2003, the Company was realigned from a single reportable business segment to three strategically focused reportable business segments: Healthcare, Life Sciences, and STERIS Isomedix Services. As the Company continues the
evolution of its business segments, the Company has made a change in the reporting of its global service business which impacts the revenues and operating results of the Healthcare and Life Sciences segments. Effective April 1, 2005, the Company
began tracking service revenues by customer account classification. Prior to April 1, 2005, the allocation between these segments was based upon geography. Segment revenues, the related costs of these revenues, and associated operating expenses have
been reclassified to reflect the change in methodology. Fiscal 2005 information presented in the following tables reflects these reclassifications.



12



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



Financial information for each of the
Companys reportable business segments is presented in the following table:



|                         |  |                            |         |   |      |   |         |  
|------------------------ |  | -------------------------- | ------- | - | ---- | - | ------- | -
|                         |  | Three Months EndedJune 30, |        
|                         |  | 2005                       |         |   | 2004 |  
|Revenues:                |  |                            |         |   |      |   |         |  
|Healthcare               |  | $                          | 185,760 |   |      | $ | 168,414 |  
|Life Sciences            |  |                            | 58,432  |   |      |   | 61,948  |  
|STERIS Isomedix Services |  |                            | 32,506  |   |      |   | 24,435  |  
|                         |  |                            |         |   |      |   |         |  
|Total revenues           |  | $                          | 276,698 |   |      | $ | 254,797 |  
|                         |  |                            |         |   |      |   |         |  
|Operating income (loss): |  |                            |         |   |      |   |         |  
|Healthcare               |  | $                          | 23,243  |   |      | $ | 24,814  |  
|Life Sciences            |  |                            | (2,331  | ) |      |   | (1,753  | )
|STERIS Isomedix Services |  |                            | 6,337   |   |      |   | 4,954   |  
|                         |  |                            |         |   |      |   |         |  
|Total operating income   |  | $                          | 27,249  |   |      | $ | 28,015  |  
|                         |  |                            |         |   |      |   |         |  



Financial information
for each of the Companys geographic areas is presented in the following table. Long-lived assets are those assets that are identified within the operations in each geographic area, including property, plant, equipment, goodwill, intangibles,
and other assets.



|                        |  |                            |              |      |   |              
|----------------------- |  | -------------------------- | ------------ | ---- | - | -------------
|                        |  | Three Months EndedJune 30,
|                        |  | 2005                       |              | 2004
|Revenues:               |  |                            |              |      |   |              
|United States           |  | $                          | 223,350      |      | $ | 204,037      
|International           |  |                            | 53,348       |      |   | 50,760       
|                        |  |                            |              |      |   |              
|Total Revenues          |  | $                          | 276,698      |      | $ | 254,797      
|                        |  |                            |              |      |   |              
|                        |  |                           
|                        |  |                            | June 30,2005 |      |   | March 31,2005
|Long-lived assets:      |  |                            |              |      |   |              
|United States           |  | $                          | 603,117      |      | $ | 607,548      
|International           |  |                            | 146,188      |      |   | 158,042      
|                        |  |                            |              |      |   |              
|Total long-lived assets |  | $                          | 749,305      |      | $ | 765,590      
|                        |  |                            |              |      |   |              



12. Repurchases of Common Shares



During the first quarter of fiscal 2006, the Company
repurchased 1,623,300 of its common shares for $39,394, representing an average price of $24.27 per common share. At June 30, 2005, 1,102,700 common shares remained authorized for repurchase and 1,908,182 common shares were held in treasury.



13. Financial and Other Guarantees



The Company generally offers a limited parts and labor warranty on its
capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the country where the Company conducts business. The Company provides for the estimated cost of product warranties at the time product
revenues are recognized. Amounts due to customers for the Companys future performance under these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets within Accrued expenses and other.
Factors that affect the Companys warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. The Company periodically assesses the adequacy
of its recorded warranty liabilities and adjusts the amounts as necessary.



13



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



Changes in the Companys warranty liability
during the first quarter of fiscal 2006 were as follows:



|                                    |  |   |        |  
|----------------------------------- |  | - | ------ | -
|Balance, March 31, 2005             |  | $ | 6,230  |  
|Warranties issued during the period |  |   | 2,585  |  
|Settlements made during the period  |  |   | (2,355 | )
|                                    |  |   |        |  
|Balance, June 30, 2005              |  | $ | 6,460  |  
|                                    |  |   |        |  



The Company also
issues product maintenance contracts to its customers that are accounted for in accordance with the requirements of FASB Technical Bulletin No. 90-1, Accounting for Separately Priced Extended Warranty and Product Maintenance Contracts.
Such contracts generally range in terms from 1 to 5 years and require the Company to maintain and repair capital products over the maintenance contract term. Amounts due from customers under these contracts are initially recorded as a liability for
deferred service contract revenue on the accompanying Consolidated Balance Sheets. The liability recorded for such deferred revenue was $13,025 and $13,081 as of June 30, 2005 and March 31, 2005, respectively. Such deferred revenues are then
amortized on a straight-line basis over the contract term and recognized as service revenues on the accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenues has been excluded from
the table presented above.



14. Foreign Currency Forward Contracts



The Company enters into foreign currency forward
contracts to hedge potential foreign currency gains and losses that arise from assets and liabilities denominated in foreign currencies, including inter-company transactions. The Company does not use derivative financial instruments for speculative
purposes. These contracts are marked to market, with gains and losses recognized on the accompanying Consolidated Statements of Income within Selling, general, and administrative expenses. At June 30, 2005, the Company had foreign
currency forward contracts outstanding to sell euros and British pounds sterling with notional amounts of 17.7 million euros and 2.4 million British pounds sterling, respectively. In addition, at June 30, 2005, the Company had entered into foreign
currency forward contracts to buy Canadian dollars with a notional amount of 21.4 million Canadian dollars.



15. Business Acquisitions



The Companys consolidated financial statements include the results of operations for acquired businesses from the date of the respective acquisition. During fiscal 2005, the Company acquired FHSurgical (on March 24, 2005), certain
assets of Cosmed Group, Inc. (on January 7, 2005), and Albert Browne Limited (on September 15, 2004). The purchase price of each acquisition has been preliminarily allocated to net assets and goodwill and is subject to further adjustment as the
Company finalizes costs associated with the respective acquisition and the valuation of their net assets. Additional information regarding recently acquired businesses is included in the Companys Annual Report on Form 10-K for the year ended
March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005.



Pursuant to the terms of the Share Purchase Agreement with respect to Hamo Holding AG (Hamo), the final settlement of certain working capital adjustments and the resolution of certain indemnification
claims were made during the first quarter of fiscal 2006. Settlement amounts received by the Company amounted to 2,150,000 Swiss francs (approximately $1.7 million) and are included in Non-operating (income) expense, net on the
Consolidated Statements of Income. Hamo was acquired by the Company during fiscal 2004.



16. Subsequent Events



Subsequent to
June 30, 2005, foreign currency forward contracts to sell euros and British pounds sterling with notional amounts of 17.7 million euros and 2.4 million British pounds sterling matured. In addition, foreign currency forward contracts to buy Canadian
dollars with a notional amount of 21.4 million Canadian dollars matured.



14



---

##### Table of Contents

STERIS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(dollars in thousands, except per share
amounts)



Subsequent to June 30, 2005, the Company entered
into foreign currency forward contracts to sell euros and British pounds sterling with notional amounts of 20.0 million euros and 2.4 million British pounds sterling. In addition, subsequent to June 30, 2005, the Company entered into foreign
currency forward contracts to buy Canadian dollars with a notional amount of 18.7 million Canadian dollars.



On July 29, 2005, the Company announced that its Board of Directors had declared a quarterly cash dividend in the amount of $.04 per common share, payable
on September 9, 2005, to shareholders of record on August 12, 2005.



15



---

##### Table of Contents

Report of Independent Registered Public Accounting Firm



Board of Directors and Shareholders

STERIS Corporation



We have reviewed the consolidated balance sheet of STERIS Corporation and subsidiaries as of June 30, 2005, and the related consolidated statements of
income and cash flows for the three-month periods ended June 30, 2005 and 2004. These financial statements are the responsibility of the Companys management.



We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A
review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance
with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.



Based upon our review, we are not aware of any material modifications that
should be made to the consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.



We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance
sheet of STERIS Corporation and subsidiaries as of March 31, 2005 and the related consolidated statements of income, shareholders equity and cash flows for the year then ended, not presented herein, and in our report dated June 9, 2005, we
expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of March 31, 2005, is fairly stated, in all material respects, in relation to
the consolidated balance sheet from which it has been derived.



/s/ Ernst & Young LLP



Cleveland, Ohio

August 4, 2005



16



---

##### Table of Contents

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS



Financial Measures.In the following sections of Managements Discussion and Analysis of Financial Condition and Results of Operations
(MD&A), the Company, at times, may refer to financial measures that are not required to be presented in the consolidated financial statements under U.S. generally accepted accounting principles. The Company has used the following
financial measures that are not required to be presented under U.S. generally accepted accounting principles in the context of this report: Backlog, debt to capital, and days sales outstanding. The Company defines these financial measures as
follows:



| |  |  | Backlog- is defined by the Company as the amount of unfilled capital purchase orders at a point in time. The Company uses this figure as a measure to assist in the projection of
short-term financial results and inventory requirements.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Debt to capital- is defined by the Company as total long-term debt divided by the sum of long-term debt and shareholders equity. The Company uses this figure as a financial
liquidity measure to gauge its ability to borrow, provide strength/protection against creditors, fund growth, develop outside of its current business operations, and measure the risk of the Companys financial structure.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Days sales outstanding(DSOs)- is defined by the Company as the average collection period for sales revenue. It is calculated as net accounts receivable divided by
the trailing four quarters revenues, multiplied by 365. The Company uses this figure to help gauge the quality of its accounts receivable and expected time to collect.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



In the following sections of MD&A, the Company, at times, may also refer to financial measures which are considered to
be non-GAAP financial measures under the rules of the Securities and Exchange Commission. Non-GAAP financial measures used by the Company are as follows:



| |  |  | Free cash flow- is defined by the Company as cash flows from operating activities as presented in the Consolidated Statements of Cash Flows less purchases of property, plant,
equipment, and intangibles, net, which is also presented in the Consolidated Statements of Cash Flows. The Company uses this measure to gauge its ability to fund future growth outside of core operations, repurchase common shares, and pay cash
dividends. The following table summarizes the calculations of the Companys free cash flow for the quarters ended June 30, 2005 and 2004:
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                                                              |      |                            |        |  |   |       
|------------------------------------------------------------- | ---- | -------------------------- | ------ |  | - | ------
|(dollars in thousands)                                        |      | Three Months EndedJune 30,
|                                                              | 2005 |                            | 2004  
|Cash flows from operating activities                          |      | $                          | 41,093 |  | $ | 42,242
|Purchases of property, plant, equipment, and intangibles, net |      |                            | 8,144  |  |   | 10,545
|                                                              |      |                            |        |  |   |       
|Free cash flow                                                |      | $                          | 32,949 |  | $ | 31,697
|                                                              |      |                            |        |  |   |       



| |  |  | The Company, at times, may refer to its results of operations excluding certain transactions or amounts that are non-recurring or are not indicative of future results, in order to
provide meaningful comparative analysis between the periods presented. For example, when discussing changes in revenues, the Company may, at times, exclude the impact of recently completed acquisitions.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



The Company has presented these financial measures because it believes that
meaningful analysis of its financial performance is enhanced by an understanding of certain additional factors underlying that performance. These financial measures should not be considered alternatives to measures required by U.S. generally
accepted accounting principles. The Companys calculations of these measures may differ from calculations of similar measures used by other companies.



Revenues- Defined.As required by Regulation S-X, the Company has presented separately on its Consolidated Statements of Income for each period presented, revenues
generated as either product revenues or service revenues. In



17



---

##### Table of Contents

discussing revenues, the Company, at times, may refer to revenues in differing detail than that which is required by
Regulation S-X. The terminology, definitions, and applications of terms that the Company uses to describe revenues may differ from terms used by other companies. The Company uses the following terms to describe revenues:



| |  |  | Revenues - The Companys revenues are presented net of sales returns and allowances.
| | - |  | ------------------------------------------------------------------------------------



| |  |  | Product Revenues - Product revenues are defined by the Company as revenues generated from sales of capital equipment, which includes steam and low temperature liquid sterilizers,
washing systems, freeze dryers, VHP® technology,
water stills, and pure steam generators; surgical lights and tables; and the consumable family of products, which includes STERIS SYSTEM 1® consumables, sterility assurance products, skin care products, and cleaning consumables.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Service Revenues - Service revenues are defined by the Company as revenues generated from parts and labor associated with the maintenance, repair, and installation of capital
equipment, as well as revenues generated from contract sterilization offered through the Companys Isomedix Services segment.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Capital Revenues - Capital revenues are defined by the Company as revenues generated from sales of capital equipment, which includes steam and low temperature liquid sterilizers,
washing systems, freeze dryers, VHP® technology,
water stills, and pure steam generators; and surgical lights and tables.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Consumable Revenues - Consumable revenues are defined by the Company as revenues generated from sales of the consumable family of products which includes STERIS SYSTEM 1® consumables, sterility assurance products, skin care
products, and cleaning consumables.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Recurring Revenues - Recurring revenues are defined by the Company as revenues generated from sales of consumable products and service revenues.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------



General Company Overview and Executive Summary.The mission of STERIS Corporation is
to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products, and services. The Companys dedicated employees around the world work
together to supply a broad range of solutions by offering a combination of equipment, consumables, and services to healthcare, pharmaceutical, industrial, and governmental customers.



STERIS participates in industries that currently benefit from strong underlying demand, with the bulk of the Companys
revenues derived from the healthcare and pharmaceutical industries. As such, much of the growth in its markets is driven by the aging of the population throughout the world, as an increasing number of individuals are entering their prime healthcare
consumption years. In addition, each of STERISs core industries are also benefiting from specific trends that drive growth. Within the healthcare market, there is increased concern regarding the level of hospital-acquired infections around the
world. The pharmaceutical industry has been impacted by increased Food & Drug Administration (FDA) scrutiny of cleaning and validation processes, mandating that manufacturers improve their processes. In the contract sterilization
industry, where Isomedix competes, an increasing trend toward the outsourcing of sterilization services continues to drive growth.



Beyond STERISs core markets, infection-control issues are becoming a global concern, and emerging threats have gained prominence in the news.
Through STERISs Life Sciences segment, the Company is actively pursuing new opportunities to adapt its proven technologies to meet the needs of emerging markets such as defense, aerospace, and industrial decontamination.



Fiscal 2006 first quarter revenues increased $21.9 million, or 8.6%, to
$276.7 million, as compared to the first quarter of fiscal 2005, driven by increased revenues within the Companys Healthcare and Isomedix Services segments. Revenue growth due to the fiscal 2005 acquisitions of Browne, FHSurgical, and certain
assets of Cosmed was 5.3% during the first quarter of fiscal 2006, and the integration of these businesses has progressed well. Organic revenue growth was 3.3% during the first quarter of fiscal 2006 and was negatively impacted by continued weakness
within the Companys Life Sciences segment, particularly related to international capital equipment sales. During the first quarter



18



---

##### Table of Contents

of fiscal 2006, the Companys gross margin percentage declined 50 basis points to 42.6% compared to the first
quarter of fiscal 2005, primarily as a result of increased prices of certain raw materials, costs related to ongoing operations of recently acquired businesses, and lower volumes within the Life Sciences segment, which resulted in lower fixed cost
absorption in certain manufacturing processes.



The
Companys financial position and cash flows remain strong. A continued focus on working capital management and reduced capital spending levels resulted in fiscal 2006 first quarter free cash flow of $32.9 million. The Company continues to
maintain low debt levels with its debt-to-capital ratio approximating 14.8% at June 30, 2005. During the fiscal 2006 first quarter, the Company continued to enhance shareholder value through a common share repurchase program, in which approximately
1.6 million common shares were repurchased at an average purchase price per share of $24.27. The Company also declared a quarterly cash dividend during the first quarter of fiscal 2006 and paid cash dividends of $0.04 per common share during the
first quarter of fiscal 2006. The Companys strong financial position and cash flows currently afford it the financial flexibility to continue to return value to shareholders in the forms of strategic acquisitions, other initiatives that
strengthen the Companys long-term competitive position, potential common share repurchases, and cash dividends.



Additional information regarding the Companys fiscal 2006 first quarter financial performance is included in the subsection below titled
Results of Operations.



Matters Affecting Comparability.



Business Acquisitions.The Companys financial results
include the results of operations for acquired businesses from the date of the respective acquisition. During fiscal 2005, the Company acquired FHSurgical (on March 24, 2005), certain assets of Cosmed Group, Inc. (on January 7, 2005), and Albert
Browne Limited (on September 15, 2004). Fiscal 2006 first quarter operating results includes aggregate revenues of $13.4 million related to these acquisitions.



International Operations. Given the nature of the Companys global operations, it maintains an inherent exposure to
fluctuations in foreign currencies. During the first quarter of fiscal 2006, the Companys revenues were favorably impacted by $2.0 million, or 0.7%, and net income was negatively impacted by $0.8 million, or 4.3%, when compared to the same
period in fiscal 2005.



Results of Operations.The following subsections
provide information regarding the Companys results of operations for the first quarter of fiscal 2006 as compared to the first quarter of fiscal 2005.



19



---

##### Table of Contents

Revenues.The following table contains information regarding the Companys revenues for the three
months ended June 30, 2005 and 2004:



|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|---------------------- | ---- | -------------------------- | ------- |  | ------ | ------- | -------------- | - | ------ | ------------------------- |  | ---- | - |  | ----- | - |  | ----- | -
|(dollars in thousands) |      | Three Months EndedJune 30, |         |  |        |         | Percent Change |   |        | Percent of Total Revenues | 
|                       | 2005 |                            | 2004    |  | Change |         |                |   | 2005   |                           |  | 2004 |  
|Capital Revenues       |      | $                          | 110,750 |  | $      | 110,762 |                | $ | (12    | )                         |  | 0.0  | % |  | 40.0  | % |  | 43.5  | %
|Consumable Revenues    |      |                            | 66,170  |  |        | 57,663  |                |   | 8,507  |                           |  | 14.8 | % |  | 23.9  | % |  | 22.6  | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|Product Revenues       |      |                            | 176,920 |  |        | 168,425 |                |   | 8,495  |                           |  | 5.0  | % |  | 63.9  | % |  | 66.1  | %
|                       |      |                            |         |  |        |        
|Service Revenues       |      |                            | 99,778  |  |        | 86,372  |                |   | 13,406 |                           |  | 15.5 | % |  | 36.1  | % |  | 33.9  | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|Total Revenues         |      | $                          | 276,698 |  | $      | 254,797 |                | $ | 21,901 |                           |  | 8.6  | % |  | 100.0 | % |  | 100.0 | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|Service Revenues       |      | $                          | 99,778  |  | $      | 86,372  |                | $ | 13,406 |                           |  | 15.5 | % |  | 36.1  | % |  | 33.9  | %
|Consumable Revenues    |      |                            | 66,170  |  |        | 57,663  |                |   | 8,507  |                           |  | 14.8 | % |  | 23.9  | % |  | 22.6  | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|Recurring Revenues     |      |                            | 165,948 |  |        | 144,035 |                |   | 21,913 |                           |  | 15.2 | % |  | 60.0  | % |  | 56.5  | %
|                       |      |                            |         |  |        |        
|Capital Revenues       |      |                            | 110,750 |  |        | 110,762 |                |   | (12    | )                         |  | 0.0  | % |  | 40.0  | % |  | 43.5  | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|Total Revenues         |      | $                          | 276,698 |  | $      | 254,797 |                | $ | 21,901 |                           |  | 8.6  | % |  | 100.0 | % |  | 100.0 | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|United States          |      | $                          | 223,350 |  | $      | 204,037 |                | $ | 19,313 |                           |  | 9.5  | % |  | 80.7  | % |  | 80.1  | %
|International          |      |                            | 53,348  |  |        | 50,760  |                |   | 2,588  |                           |  | 5.1  | % |  | 19.3  | % |  | 19.9  | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  
|Total Revenues         |      | $                          | 276,698 |  | $      | 254,797 |                | $ | 21,901 |                           |  | 8.6  | % |  | 100.0 | % |  | 100.0 | %
|                       |      |                            |         |  |        |         |                |   |        |                           |  |      |   |  |       |   |  |       |  



Revenues increased
$21.9 million, or 8.6%, to $276.7 million for the quarter ended June 30, 2005, as compared to $254.8 million for the comparable prior year quarter. As compared to the first quarter of fiscal 2005, recurring revenues increased $21.9 million, or
15.2%. The recurring revenues increase was generated from a 15.5% increase in service revenues and a 14.8% increase in consumable revenues. Within the Healthcare and Life Sciences segments, service revenues increased 9.6% and 6.1%, respectively,
quarter-over-quarter. Capital revenues remained flat quarter-over-quarter as a result of continued weakness in the Companys Life Sciences segment, particularly within the international pharmaceutical marketplace, which offset the 7.5% increase
in Healthcare capital revenues.



International revenues
increased $2.6 million, or 5.1%, to $53.3 million, for the quarter ended June 30, 2005, as compared to $50.8 million for the comparable prior year quarter. International revenues were positively impacted by strong recurring and capital revenues
growth within the international Healthcare marketplace. The international recurring revenues growth was driven by additional revenues generated from sales of consumable products from the recently acquired Browne business. International Healthcare
capital revenues were positively impacted by sales generated from the recently acquired FHSurgical business. Within the Companys Life Sciences segment, international capital equipment sales declined 62.1%, which offset the positive growth in
international Healthcare revenues.



United States revenues
increased $19.3 million, or 9.5%, to $223.4 million, for the quarter ended June 30, 2005, as compared to $204.0 million for the comparable prior year quarter. United States revenues benefited from strong performance in the Isomedix Services segment,
which was comprised of 7.3% organic revenue growth and 25.7% acquisition-related revenue growth associated with Cosmed. Quarter-over-quarter, United States Life Sciences capital revenues increased 39.7%, and also served to drive the Companys
overall United States revenue growth. United States revenues also benefited from strong underlying demand for the Companys service offerings, particularly in the Healthcare segment.



Revenues are further discussed on a segment basis in the section of MD&A titled Business Segment Results of
Operations.



20



---

##### Table of Contents

Gross Profit.The following table contains information regarding the Companys gross profit for the
three months ended June 30, 2005 and 2004:



|                              |      |                            |         |      |  |   |                |   |  |   |       |  |      |  
|----------------------------- | ---- | -------------------------- | ------- | ---- |  | - | -------------- | - |  | - | ----- |  | ---- | -
|(dollars in thousands)        |      | Three Months EndedJune 30, |         |      |  |   | Percent Change |  
|                              | 2005 |                            |         | 2004 |  |   | Change         |  
|Gross Profit:                 |      |                            |         |      |  |   |                |   |  |   |       |  |      |  
|Product                       |      | $                          | 75,282  |      |  | $ | 73,231         |   |  | $ | 2,051 |  | 2.8  | %
|Service                       |      |                            | 42,489  |      |  |   | 36,661         |   |  |   | 5,828 |  | 15.9 | %
|                              |      |                            |         |      |  |   |                |   |  |   |       |  |      |  
|Total Gross Profit            |      | $                          | 117,771 |      |  | $ | 109,892        |   |  | $ | 7,879 |  | 7.2  | %
|                              |      |                            |         |      |  |   |                |   |  |   |       |  |      |  
|Gross Profit Percentage:      |      |                            |         |      |  |   |                |   |  |   |       |  |      |  
|Product                       |      |                            | 42.6    | %    |  |   | 43.5           | % |  |   |       |  |      |  
|Service                       |      |                            | 42.6    | %    |  |   | 42.4           | % |  |   |       |  |      |  
|                              |      |                            |         |      |  |   |                |   |  |   |       |  |      |  
|Total Gross Profit Percentage |      |                            | 42.6    | %    |  |   | 43.1           | % |  |   |       |  |      |  
|                              |      |                            |         |      |  |   |                |   |  |   |       |  |      |  



Gross profit (margin)
is impacted by the volume, pricing, and mix of sales of the Companys products and services, as well as the costs associated with the products and services that are sold. Period-over-period, the Companys gross margin decreased 50 basis
points. Gross margins for the first quarter of fiscal 2006 were negatively impacted by higher raw materials prices, particularly related to stainless steel and certain petroleum-based chemicals. Gross margins were also negatively impacted by direct
costs associated with the operations of recently acquired businesses and reduced volumes within the Life Sciences segment, which resulted in lower fixed cost absorption within certain manufacturing processes.



Operating Expenses. The following table contains information regarding the
Companys operating expenses for the three months ended June 30, 2005 and 2004:



|                                     |      |                            |        |  |        |        |                |   |       |   |  |      |  
|------------------------------------ | ---- | -------------------------- | ------ |  | ------ | ------ | -------------- | - | ----- | - |  | ---- | -
|(dollars in thousands)               |      | Three Months EndedJune 30, |        |  |        |        | Percent Change |  
|                                     | 2005 |                            | 2004   |  | Change |        |               
|Operating Expenses:                  |      |                            |        |  |        |        |                |   |       |   |  |      |  
|Selling, General, and Administrative |      | $                          | 81,793 |  | $      | 72,566 |                | $ | 9,227 |   |  | 12.7 | %
|Research and Development             |      |                            | 8,729  |  |        | 9,311  |                |   | (582  | ) |  | -6.3 | %
|                                     |      |                            |        |  |        |        |                |   |       |   |  |      |  
|Total Operating Expenses             |      | $                          | 90,522 |  | $      | 81,877 |                | $ | 8,645 |   |  | 10.6 | %
|                                     |      |                            |        |  |        |        |                |   |       |   |  |      |  



Significant components
of total Selling, General, and Administrative expenses (SG&A) are compensation and benefit costs, fees for professional services, travel and entertainment, facilities costs, and other general and administrative expenses. As a
percentage of total revenues, SG&A increased 110 basis points to 29.6% for the first quarter of fiscal 2006 as compared to 28.5% during the first quarter of fiscal 2005. The increase in SG&A period-over-period resulted primarily from direct
costs associated with the operations of recently acquired businesses. The Company also experienced higher professional fees as a result of various strategic initiatives.



As a percentage of total revenues, research and development expenses were 3.2% and 3.7% for the quarters ended June 30, 2005
and 2004, respectively. Research and development expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. The Company continues to focus research and development efforts
on product development, product improvements, and the development of new technological innovations. Research and development efforts continue to be focused in the defense and industrial areas, sterile processing combination technologies, and the
area of prions, or infectious proteins.



Non-Operating
(Income) Expense, Net.The following table contains information regarding the Companys non-operating (income) expense, net for the three months ended June 30, 2005 and 2004:



|                                     |      |                            |        |      |  |   |        |   |  |   |      
|------------------------------------ | ---- | -------------------------- | ------ | ---- |  | - | ------ | - |  | - | -----
|(dollars in thousands)               |      | Three Months EndedJune 30, |        |      | 
|                                     | 2005 |                            |        | 2004 |  |   | Change
|Non-Operating (Income) Expense, Net: |      |                            |        |      |  |   |        |   |  |   |      
|Interest Expense                     |      | $                          | 1,221  |      |  | $ | 987    |   |  | $ | 234  
|Interest and Miscellaneous Income    |      |                            | (1,927 | )    |  |   | (286   | ) |  |   | 1,641
|                                     |      |                            |        |      |  |   |        |   |  |   |      
|Non-Operating (Income) Expense, Net  |      | $                          | (706   | )    |  | $ | 701    |   |  |   | NM   
|                                     |      |                            |        |      |  |   |        |   |  |   |      



Non-operating (income)
expense, net consists of interest expense on debt, offset by interest earned on cash, cash equivalents, short-term investment balances, and other miscellaneous income.



21



---

##### Table of Contents

Interest expense increased $0.2 million period-over-period as a result of higher average debt levels and
higher interest rates during the first quarter of fiscal 2006 as compared to the first quarter of fiscal 2005. Interest and other miscellaneous income increased $1.6 million period-over-period. This increase resulted primarily from the final
settlement of certain working capital adjustments and the resolution of certain indemnification claims pursuant to the terms of the Share Purchase Agreement with respect to Hamo Holding AG (Hamo), which was acquired by the Company during
fiscal 2004.



Income Tax Expense. The following table contains
information regarding the Companys income tax expense and effective income tax rates for the three months ended June 30, 2005 and 2004:



|                          |      |                            |        |      |        |   |                |   |  |   |     |  |     |  
|------------------------- | ---- | -------------------------- | ------ | ---- | ------ | - | -------------- | - |  | - | --- |  | --- | -
|(dollars in thousands)    |      | Three Months EndedJune 30, |        |      | Change |   | Percent Change |  
|                          | 2005 |                            |        | 2004 |        |   |               
|Income Tax Expense        |      | $                          | 10,623 |      |        | $ | 9,697          |   |  | $ | 926 |  | 9.5 | %
|Effective Income Tax Rate |      |                            | 38.0   | %    |        |   | 35.5           | % |  |   |     |  |     |  



The Company provides
for income tax expense on an interim basis based upon the Companys estimate of the annual effective income tax rate. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of
the Companys annual earnings and the taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the Companys ability to use tax credits and net operating loss carryforwards, and available
tax planning alternatives. The Companys effective income tax rate was 38.0% for the first quarter of fiscal 2006 as compared to 35.5% for the first quarter of fiscal 2005. The higher effective income tax rate for the first quarter of fiscal
2006 resulted from a reduction of operating profits generated in international tax jurisdictions and the resulting inability of the Company to utilize a portion of foreign tax credits against foreign profits taxed in the United States.



Business Segment Results of Operations.Certain reclassifications have been
made to previously reported segment revenues, the related costs of these revenues, and associated operating expenses. These reclassifications are further discussed in Note 11 to the Companys consolidated financial statements, Business
Segment Information. Information presented in the following tables and related discussion regarding segment revenues and operating results reflect these changes.



The Company operates and reports in three business segments: Healthcare, Life Sciences, and STERIS Isomedix
Services. Additional information regarding the Companys business segments is included in the Companys Annual Report on Form 10-K for the year ended March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005. The
following table contains information regarding business segment revenues for the three months ended June 30, 2005 and 2004:



|                         |      |                            |         |        |   |         |                |   |        |   |  |      |  
|------------------------ | ---- | -------------------------- | ------- | ------ | - | ------- | -------------- | - | ------ | - |  | ---- | -
|(dollars in thousands)   |      | Three Months EndedJune 30, |         | Change |   |         | Percent Change |  
|                         | 2005 |                            | 2004    |        |  
|Revenues:                |      |                            |         |        |   |         |                |   |        |   |  |      |  
|Healthcare               |      | $                          | 185,760 |        | $ | 168,414 |                | $ | 17,346 |   |  | 10.3 | %
|Life Sciences            |      |                            | 58,432  |        |   | 61,948  |                |   | (3,516 | ) |  | -5.7 | %
|STERIS Isomedix Services |      |                            | 32,506  |        |   | 24,435  |                |   | 8,071  |   |  | 33.0 | %
|                         |      |                            |         |        |   |         |                |   |        |   |  |      |  
|Total Revenues           |      | $                          | 276,698 |        | $ | 254,797 |                | $ | 21,901 |   |  | 8.6  | %
|                         |      |                            |         |        |   |         |                |   |        |   |  |      |  



Healthcare segment
revenues represented 67.2% of total revenues for the first quarter of fiscal 2006 as compared to 66.1% for the comparable prior year quarter. Healthcare revenues increased $17.3 million, or 10.3%, to $185.8 million for the quarter ended June 30,
2005, as compared to $168.4 million for the first quarter of fiscal 2005. The increase in Healthcare revenues was driven by a 12.6% increase in recurring revenues. Strong service revenues within the United States marketplace and increased
international consumable revenues primarily related to the recently-acquired Browne business fueled the increase. Capital revenues, which benefited from the FHSurgical acquisition, increased 7.5% quarter-over-quarter, primarily within the Healthcare
segments international marketplace. At June 30, 2005, the Healthcare segments backlog amounted to $70.7 million, representing increases of $5.3 million, or 8.1%, and $6.4 million, or 9.9%, over the March 31, 2005 and June 30, 2004
levels, respectively.



22



---

##### Table of Contents

Life Sciences segment revenues represented 21.1% of total revenues for the first quarter of fiscal 2006
as compared to 24.3% for the comparable prior year quarter. Life Sciences revenues decreased $3.5 million, or 5.7%, to $58.4 million for the quarter ended June 30, 2005, as compared to $61.9 million for the first quarter of fiscal 2005. The
reduction in Life Sciences revenues was driven by a 16.3% decrease in capital revenues. Positive capital revenue growth of 39.7% within the United States marketplace was offset by continued weakness in demand within the international pharmaceutical
marketplace where capital revenues decreased 62.1%. The overall decline in capital revenues within the segment was partially offset by 11.2% and 6.1% increases in consumable and service revenues, respectively. At June 30, 2005, the Life Sciences
segments backlog amounted to $53.6 million, representing decreases of $12.5 million, or 18.9%, and $15.5 million, or 22.4%, over the March 31, 2005 and June 30, 2004 levels, respectively.



STERIS Isomedix Services segment revenues represented 11.7% of total revenues
for the first quarter of fiscal 2006 as compared to 9.6% for the comparable prior year quarter. The segment experienced revenue growth of $8.1 million, or 33.0%, to $32.5 million during the first quarter of fiscal 2006, as compared to the same prior
year quarter. Revenues generated through organic growth remained strong at 7.3%, quarter-over-quarter. The integration of Cosmed to the segments operations contributed 25.7% to the segments revenue growth rate during the first quarter of
fiscal 2006.



The following table contains information
regarding business segment operating income (loss) for the three months ended June 30, 2005 and 2004:



|                         |      |                            |        |      |        |   |        |               |  |   |        |   |  |      |  
|------------------------ | ---- | -------------------------- | ------ | ---- | ------ | - | ------ | ------------- |  | - | ------ | - |  | ---- | -
|(dollars in thousands)   |      | Three Months EndedJune 30, |        |      | Change |   |        | PercentChange | 
|                         | 2005 |                            |        | 2004 |        |   |       
|Operating Income (Loss): |      |                            |        |      |        |   |        |               |  |   |        |   |  |      |  
|Healthcare               |      | $                          | 23,243 |      |        | $ | 24,814 |               |  | $ | (1,571 | ) |  | -6.3 | %
|Life Sciences            |      |                            | (2,331 | )    |        |   | (1,753 | )             |  |   | (578   | ) |  | 33.0 | %
|STERIS Isomedix Services |      |                            | 6,337  |      |        |   | 4,954  |               |  |   | 1,383  |   |  | 27.9 | %
|                         |      |                            |        |      |        |   |        |               |  |   |        |   |  |      |  
|Total Operating Income   |      | $                          | 27,249 |      |        | $ | 28,015 |               |  | $ | (766   | ) |  | -2.7 | %
|                         |      |                            |        |      |        |   |        |               |  |   |        |   |  |      |  



To determine
segment operating income (loss), the Company reduces the respective segments gross profit by direct expenses and indirect cost allocations, which reflect the full allocation of all distribution, corporate, and research and development
expenses. Corporate cost allocations are based on each segments portion of revenues, headcount, or other variables in relation to the total Company.



Healthcare segment operating income decreased $1.6 million, or 6.3%, to $23.2 million for the first quarter of fiscal 2006, as compared to $24.8 million
for the comparable prior year quarter. Healthcare segment operating margins were 12.5% and 14.7% for the quarters ended June 30, 2005 and 2004, respectively. Increased raw material costs related to stainless steel and certain petroleum-based
chemicals negatively impacted operating results and margins during the quarter ended June 30, 2005. Operating margins for the first quarter of fiscal 2006 also reflect additional direct costs associated with the operations of recently acquired
businesses.



Life Sciences segment operating loss was $2.3
million and $1.8 million for the quarters ended June 30, 2005 and 2004, respectively. The segments operating results were negatively impacted by reduced volumes and the resulting lower fixed cost absorption, along with increased raw material
costs.



STERIS Isomedix Services segment operating income
increased $1.4 million, or 27.9%, to $6.3 million for the first quarter of fiscal 2006 as compared to $5.0 million for the comparable prior year period, primarily due to increased volumes within the segment. The segments operating margins were
19.5% and 20.3% for the quarters ended June 30, 2005 and 2004, respectively. For the first quarter of fiscal 2006, the segments margins remained strong, but declined from the comparable prior year period as a result of direct costs associated
with the operations of the recently acquired assets of Cosmed.





23



---

##### Table of Contents

Liquidity and Capital Resources.The following table summarizes significant components of the Companys cash
flows for the three months ended June 30, 2005 and 2004:



Cash Flows



|                                                                                            |  |                            |         |   |      |   |         |  
|------------------------------------------------------------------------------------------- |  | -------------------------- | ------- | - | ---- | - | ------- | -
|                                                                                            |  | Three Months EndedJune 30, |        
|(dollars in thousands)                                                                      |  | 2005                       |         |   | 2004 |  
|                                                                                            | 
|Operating activities:                                                                       |  |                            |         |   |      |   |         |  
|Net income                                                                                  |  | $                          | 17,332  |   |      | $ | 17,617  |  
|Non-cash items                                                                              |  |                            | 13,129  |   |      |   | 17,898  |  
|Changes in operating assets and liabilities, excluding the effects of business acquisitions |  |                            | 10,632  |   |      |   | 6,727   |  
|                                                                                            |  |                            |         |   |      |   |         |  
|Net cash provided by operating activities                                                   |  | $                          | 41,093  |   |      | $ | 42,242  |  
|                                                                                            |  |                            |         |   |      |   |         |  
|Investing activities:                                                                       |  |                            |         |   |      |   |         |  
|Purchases of property, plant, equipment, and intangibles, net                               |  | $                          | (8,144  | ) |      | $ | (10,545 | )
|                                                                                            |  |                            |         |   |      |   |         |  
|Net cash used in investing activities                                                       |  | $                          | (8,144  | ) |      | $ | (10,545 | )
|                                                                                            |  |                            |         |   |      |   |         |  
|Financing activities:                                                                       |  |                            |         |   |      |   |         |  
|Proceeds (payments) under credit facilities, net                                            |  | $                          | 21,600  |   |      | $ | (5,247  | )
|Payments on long-term obligations and capital leases, net                                   |  |                            | (1,675  | ) |      |   | (1,118  | )
|Repurchases of common shares                                                                |  |                            | (39,394 | ) |      |   | (28,149 | )
|Cash dividends paid to common shareholders                                                  |  |                            | (2,767  | ) |      |   |        |  
|Deferred financing fees                                                                     |  |                            | (217    | ) |      |   |        |  
|Stock option and other equity transactions, net                                             |  |                            | 1,603   |   |      |   | 2,646   |  
|                                                                                            |  |                            |         |   |      |   |         |  
|Net cash used in financing activities                                                       |  | $                          | (20,850 | ) |      | $ | (31,868 | )
|                                                                                            |  |                            |         |   |      |   |         |  
|Debt-to-capital ratio                                                                       |  |                            | 14.8    | % |      |   | 13.5    | %
|                                                                                            |  |                           
|Free cash flow                                                                              |  | $                          | 32,949  |   |      | $ | 31,697  |  



Net Cash Provided by Operating
Activities. Net cash provided by operating activities was $41.1 million for the first quarter of fiscal 2006 as compared to $42.2 million for the first quarter of fiscal 2005. Operating cash flows were derived as follows:



| |  |  | Non-cash items- Non-cash items were $13.1 million for the first quarter of fiscal 2006 as compared to $17.9 million for the first quarter of fiscal 2005. Non-cash items include
depreciation, depletion, and amortization, changes in deferred income taxes, and other items. The most significant component of non-cash items in both periods presented is depreciation, depletion, and amortization, which amounted to $13.9 million
and $11.7 million for the first quarters of fiscal 2006 and 2005, respectively. The $2.2 million increase in depreciation, depletion, and amortization, period-over-period, is the result of increased levels of depreciable assets and intangibles,
driven primarily by the fiscal 2005 acquisitions of Browne and Cosmed.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Working capital- Excluding the impact of foreign currency translation adjustments and balances acquired from business acquisitions, changes to the Companys working capital
amounted to $10.6 million and $6.7 million during the first quarters of fiscal 2006 and 2005, respectively. Information regarding significant components of the Companys fiscal 2006 first quarter working capital change is as follows (excluding
the impact of foreign currency translation adjustments and balances acquired from business acquisitions):
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Accounts receivable, net- Accounts receivable, net decreased $55.5 million during the quarter ended June 30, 2005. Accounts receivable balances are influenced by the timing of
revenues, customer collections, and progress billings for contracts that are accounted for under the percentage of completion method of accounting for construction-type contracts. Accounts receivable days sales outstanding decreased to 72 days
during the quarter ended June 30, 2005, from 92 days at March 31, 2005. The decrease in DSOs from the March 31, 2005 level is reflective of more aggressive collection efforts and enhanced collection procedures.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Inventories, net- Inventories, net increased $12.4 million during the quarter ended June 30, 2005. The Company has established targeted inventory production levels at certain
manufacturing facilities in a
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



24



---

##### Table of Contents

process called modified level-loading, whereby a relatively constant stream of inventory production
occurs, which may result in varying inventory levels during the year as a result of customer demand fluctuations.



| |  |  | Accounts payable, net- Accounts payable, net decreased $14.2 million during the first quarter of fiscal 2006 due primarily to varying payment due dates of accounts payable
obligations and the Companys cash management strategies.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Accruals and other, net- Accruals and other, net decreased $15.8 million during the quarter ended June 30, 2005. The decrease in accruals and other, net during the quarter was
driven by the timing of payments under the Companys management incentive compensation programs. A reduction of accruals under various employee commission programs and a decrease in deferred revenues also contributed to the decrease in accruals
and other, net during the quarter. These amounts are influenced by the timing and mix of revenues. These decreases were partially offset by the federal income tax provision for the first quarter of fiscal 2006.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Net Cash Used In Investing Activities.During the first quarter of fiscal 2006,
capital expenditures amounted to $8.1 million as compared to $10.5 million during the first quarter of fiscal 2005. Lower capital spending levels during the first quarter of fiscal 2006 resulted primarily from the completion of several in process
facilities expansion projects and information technology initiatives during the latter half of fiscal 2005.



Net Cash Used In Financing Activities.Net cash used in financing activities amounted to $20.9 million for the first quarter of fiscal 2006 as compared to $31.9 million for the first quarter of fiscal
2005. Information regarding the significant components of the Companys financing cash flows for the periods presented follows:



| |  |  | Proceeds (payments) under credit facilities, net- During the first quarter of fiscal 2006, net proceeds from the Companys credit facility amounted to $21.6 million as compared
to net payments under various credit facilities of $5.2 million during the prior year first quarter. Net proceeds from the credit facility during the first quarter of fiscal 2006 were used, in part, to fund the quarters repurchases of common
shares, provide flexibility in working capital management, and for other general corporate purposes. Net payments made during the first quarter of fiscal 2005 related primarily to payments made on Hamo bank facilities.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Repurchases of common shares- During the first quarter of fiscal 2006, the Company repurchased 1,623,300 of its common shares at an average purchase price of $24.27 per common
share, as compared to 1,265,100 of its common shares at an average purchase price of $22.25 per common share during the first quarter of fiscal 2005.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Cash dividends paid to common shareholders- During the first quarter of fiscal 2006, the Company paid a cash dividend of $0.04 per outstanding common share to shareholders of record
on May 31, 2005. Total cash dividends paid amounted to $2.8 million. The Company did not pay cash dividends during the comparable prior year quarter.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Stock option and other equity transactions, net- Cash flows from stock option and other equity transactions, net are primarily derived from the issuance of the Companys common
shares under various employee stock compensation programs. During the first quarters of fiscal 2006 and 2005, cash proceeds from the issuance of common shares under these programs totaled $1.5 million and $4.4 million, respectively.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Cash Requirements.The Company currently intends to fund
short-term and long-term capital expenditures, as well as liquidity needs, with existing cash and cash equivalent balances and its existing credit facility, as well as cash generated by operations. The Company believes that these sources will be
sufficient to meet working capital needs, capital requirements, and commitments for at least the next twelve months. However, the Companys capital requirements will depend on many factors, including the Companys rate of sales growth,
market acceptance of the Companys products and services, costs of securing access to adequate manufacturing capacities, the timing and extent of research and development projects, and changes in operating expenses, all of which are subject to
uncertainty. To the extent that the Companys existing sources of cash are insufficient to fund the Companys future activities, the Company may need to raise additional funds through public or private debt or equity financing. Additional
funds may not be available on favorable terms to the Company, or at all.





25



---

##### Table of Contents

Sources of Credit and Contractual and Commercial Commitments.Information regarding the Companys sources of
credit and contractual and commercial commitments is included in the Companys Annual Report on Form 10-K for the year ended March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005. The Companys commercial
commitments are approximately $41.3 million at June 30, 2005 reflecting a net decline of $32.2 million in surety bonds and other commercial commitments from March 31, 2005. The Companys contractual commitments have not changed materially from
March 31, 2005. The maximum aggregate borrowing limits under the Credit Agreement of the Company described below have not changed since March 31, 2005. At June 30, 2005, the maximum amount available under this Credit Agreement was $216.2 million.
The maximum aggregate borrowing limit of $275.0 million under the Credit Agreement is reduced by outstanding amounts and letters of credit issued under a sub-limit within the Credit Agreement. At June 30, 2005, these amounts totaled $22.8 million
and $36.0 million, respectively.



As of June 16, 2005, the
Company entered into Amendment No. 2 (Amendment No. 2) to the Amended and Restated Credit Agreement (the Credit Agreement) dated March 29, 2004 with KeyBank National Association, as administrative agent for the lending
institutions party thereto, and with such lending institutions. Among other things, Amendment No. 2 modified the Companys existing Credit Agreement to amend the facility fee rates and applicable margins, extend the length of the facility to
June 15, 2010, increase the swing line commitment component of the Credit Facility to $35.0 million, and relax certain covenants.



Critical Accounting Policies, Estimates, and Assumptions.Information related to the Companys critical accounting policies, estimates, and assumptions is
included in the Companys Annual Report on Form 10-K for the year ended March 31, 2005, filed with the Securities and Exchange Commission on June 14, 2005. The Companys critical accounting policies, estimates, and assumptions have not
changed materially from March 31, 2005.



Contingencies.The Company is
involved in various patent, product liability, consumer, environmental, tax proceedings and claims, governmental investigations, and other legal and regulatory proceedings that arise from time to time in the ordinary course of business. In
accordance with Statement of Financial Accounting Standards No. 5, Accounting for Contingencies, the Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is both probable and
estimable. The Company considers many factors in making these assessments, including the professional judgment of experienced members of management and the Companys legal counsel. The Company has made estimates as to the likelihood of
unfavorable outcomes and the amounts of such potential losses. In the opinion of management, the ultimate outcome of these proceedings and claims is not anticipated to have a material adverse effect on the Companys consolidated financial
position, results of operations, or cash flows. Litigation is inherently unpredictable and actual results could materially differ from the Companys estimates. The Company records anticipated recoveries under applicable insurance contracts when
assured of recovery.



To the extent that management of the
Company believes it is probable that a taxing authority will take a sustainable position on a matter contrary to the position taken by the Company, the Company provides tax accruals. If the Company was to prevail in matters for which accruals have
been established, or is required to pay amounts in excess of established accruals, the Companys effective income tax rate in a given financial statement period could be materially impacted.



International Operations.Given the nature of the Companys global operations, it
maintains an inherent exposure to fluctuations in foreign currencies. During the first quarter of fiscal 2006, the Companys revenues were favorably impacted by $2.0 million, or 0.7%, and net income was negatively impacted by $0.8 million, or
4.3%, when compared to the same period in fiscal 2005. The Company cannot predict with certainty future changes in foreign currency exchange rates or the effect they will have on the Companys operations.



Forward-Looking Statements.This document may contain statements concerning certain
trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded forward-looking statements under the Private
Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as may, will,
expects, believes, anticipates, plans, estimates, projects, targets, forecasts, and seeks, or the negative of such terms or other variations
on



26



---

##### Table of Contents

such terms or comparable terminology. Many important factors could cause actual results to differ materially from those
in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in
government regulations or the application or interpretation thereof. Many of these important factors are outside STERISs control. No assurances can be provided as to any future financial results. Unless legally required, the Company does not
undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially
from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing or raw material cost that leads to erosion of profit margins, (b) the possibility that market demand will not develop for
new technologies, products or applications, or the Companys business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings,
regulations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of
international unrest or effects of fluctuations in foreign currencies of countries where the Company does a sizeable amount of business, and (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Companys
products and services.



Availability of Securities and Exchange Commission
Filings.The Company files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, amendments to those reports, and other information with the Securities and Exchange Commission (SEC). Copies of
these materials can be obtained by visiting the SECs Public Reference Room at 450 Fifth Street, NW, Washington, D.C. 20549, or by accessing the SECs website at http://www.sec.gov. Information on the Public Reference Room
may be obtained by calling the SEC at 1-800-SEC-0330. In addition, as soon as reasonably practicable after such materials are filed with or furnished to the SEC, the Company makes copies available to the public, free of charge, on or through the
investor relations section of its website at http://www.steris-ir.com. Information on the Companys website is not incorporated by reference into this report.



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK



In the ordinary course of business, the Company is subject to interest rate, foreign currency, and commodity risks. Information related to these risks and
the Companys management of these exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosures about Market Risk, included in the Companys Annual Report on Form 10-K for the year ended March 31, 2005,
filed with the Securities and Exchange Commission on June 14, 2005. The Companys exposures to market risks have not changed materially since March 31, 2005.



ITEM 4. CONTROLS AND PROCEDURES



Under the supervision of and with the participation of the Companys management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), the Company evaluated the effectiveness of the
design and operation of its disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as of the end of the period covered by this Quarterly Report. Based on that
evaluation, the Companys management, including the CEO and CFO, concluded that as of June 30, 2005, the Companys disclosure controls and procedures were effective.



There were no changes in the Companys internal control over financial reporting as defined in Rules 13a-15(f) and
15d-15(f) of the Securities Exchange Act of 1934, that occurred during the quarter ended June 30, 2005, that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting.



27



---

##### Table of Contents

PART II - OTHER INFORMATION



ITEM 1. LEGAL PROCEEDINGS



The
Company is involved in a number of legal proceedings and claims, which the Company believes arise from the ordinary course of its business, given its size, history, complexity, nature of its business, and industries in which it participates. These
legal proceedings and claims generally involve a variety of legal theories and allegations, including without limitation, personal injury (e.g., slip and falls, automobile accidents), product liability (e.g., based on the operation or claimed
malfunction of products), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants), property damage (e.g., claimed damage due to leaking equipment, fire), economic loss (e.g., breach of contract, other commercial claims),
employment (e.g., wrongful termination), and other claims for damage and relief.



The FDA and the U.S. Department of Justice are conducting an investigation believed to involve the Companys SYSTEM 1® sterile processing system. In January 2005, the Company received a subpoena for documents in connection with the investigation. The Company is
currently responding to this subpoena and has offered and intends to cooperate with the government agencies regarding this matter.



The Company believes it has adequately reserved for its current litigation and that the ultimate outcome of its pending lawsuits and claims will not have
a material adverse effect on the Companys consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome of current or future litigation,
proceedings, investigations, or claims or their effect. The Company presently maintains product liability insurance coverage, and other liability coverage in amounts and with deductibles that it believes are prudent.



From time to time, STERIS is also involved in legal proceedings as a
plaintiff involving contract, patent protection, and other claims asserted by the Company. Gains, if any, from these proceedings are recognized when they are realized.



The Company believes there have been no material recent developments concerning the Companys legal proceedings since
March 31, 2005 and no new material pending legal proceedings required to be reported.



ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS



During the first quarter of fiscal 2006, the Company repurchased 1,623,300 of its common shares. These repurchases were pursuant to a single repurchase
program which was approved by the Companys Board of Directors and announced on July 28, 2004. This common share repurchase authorization replaced the common share repurchase authorization of July 24, 2002. The following table summarizes the
common shares repurchased during the first quarter of fiscal 2006 under the Companys common share repurchase program.



28



---

##### Table of Contents

Issuer Purchases of Equity Securities



|                                     |  |                                 |  |                             |       |                                                                              |           |                                                                             |          
|------------------------------------ |  | ------------------------------- |  | --------------------------- | ----- | ---------------------------------------------------------------------------- | --------- | --------------------------------------------------------------------------- | ---------
|Period                               |  | Total Number ofShares Purchased |  | Average PricePaid Per Share |       | Total Number ofShares PurchasedAs Part of PubliclyAnnounced Plansor Programs |           | Maximum Numberof Shares that MayYet Be PurchasedUnder the Plans or Programs
|April 1, 2005 through April 30, 2005 |  |                                |  | $                           |      |                                                                              |          |                                                                             | 2,726,000
|May 1, 2005 through May 31, 2005     |  | 903,600                         |  |                             | 23.88 |                                                                              | 903,600   |                                                                             | 1,822,400
|June 1, 2005 through June 30, 2005   |  | 719,700                         |  |                             | 24.76 |                                                                              | 719,700   |                                                                             | 1,102,700
|                                     |  |                                 |  |                             |       |                                                                              |           |                                                                             |          
|Total                                |  | 1,623,300                       |  | $                           | 24.27 |                                                                              | 1,623,300 |                                                                             | 1,102,700
|                                     |  |                                 |  |                             |       |                                                                              |           |                                                                             |          



ITEM 6. EXHIBITS



(a) Exhibits:



|               |  |                                                                                                                                                                                                                                                                                                                                                                 
|-------------- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Exhibit Number |  | Exhibit Description                                                                                                                                                                                                                                                                                                                                             
|3.1            |  | 1992 Amended Articles of Incorporation of STERIS Corporation, as amended on May 14, 1996, November 6, 1996, and August 6, 1998 (filed as Exhibit 3.1 to Form 10-K filed for the fiscal year
ended March 31, 2000 (Commission File No. 1-14643), and incorporated herein by reference).                                                                          
|               | 
|3.2            |  | Amended and Restated Regulations of STERIS Corporation (filed as Exhibit 3.2 to Form 10-Q for the fiscal quarter ended September 30, 2004, as originally filed (Commission File No. 1-14643),
and incorporated herein by reference).                                                                                                                            
|               | 
|4.1            |  | Specimen Form of Common Stock Certificate (filed as Exhibit 4.1 to Form 10-K filed for the fiscal year ended March 31, 2002 (Commission File No. 1-14643), and incorporated herein by
reference).                                                                                                                                                               
|               | 
|4.2            |  | Amended and Restated Rights Agreement, dated as of January 21, 1999, between STERIS Corporation and National City Bank, as successor Rights Agent (filed as Exhibit 4.2 to the Registration
Statement on Form 8-A filed April 16, 1999 (Commission File No. 1-14643), and incorporated herein by reference).                                                    
|               | 
|4.3            |  | Amendment No. 1, dated June 7, 2002, to Amended and Restated Rights Agreement, dated as of January 21, 1999, between STERIS Corporation and National City Bank, as successor Rights Agent
(filed as Exhibit 4.1 to the Registration Statement on Form 8-A/A filed June 10, 2002 (Commission File No. 1-14643), and incorporated herein by reference).           
|               | 
|10.1           |  | Executive Retention Agreement between STERIS Corporation and Dr. Peter A. Burke.                                                                                                                                                                                                                                                                                
|               | 
|10.2           |  | Amendment No. 2 to Amended and Restated Credit Agreement dated March 29, 2004 with KeyBank National Association, as administrative agent for the lending institutions party thereto, and such
institutions (filed as Exhibit 10.1 to the Current Report on Form 8-K filed on June 21, 2005 (Commission File No. 1-14643), and incorporated herein by reference).



29



---

##### Table of Contents

|     |  |                                                                                                                                                                               
|---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|15.1 |  | Letter Re: Unaudited Interim Financial Information.                                                                                                                           
|     | 
|31.1 |  | Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                       
|     | 
|31.2 |  | Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                       
|     | 
|32.1 |  | Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant Section 906 of the Sarbanes-Oxley Act of 2002.





30



---

##### Table of Contents

SIGNATURE



Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



STERIS Corporation/s/ Laurie BrlasLaurie BrlasSenior Vice President and Chief Financial Officer August 9, 2005